Polaris Group (TPE:6550)

Market Cap	23.04B
Revenue (ttm)	70.83M
Net Income (ttm)	-3.01B
Shares Out	770.47M
EPS (ttm)	-3.93
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	546,401
Average Volume	580,965
Open	31.20
Previous Close	31.00
Day's Range	29.90 - 31.20
52-Week Range	26.35 - 52.00
Beta	0.14
RSI	40.52
Earnings Date	Nov 11, 2025

About Polaris Group

Polaris Group, together with its subsidiaries, offers biotechnology, drug testing, and contract development and manufacturing services. The company engages in the research, development, manufacture and sale of new drugs. It develops ADI-PEG 20 for the treatment of various cancer indications, as well as provides healthcare consulting, staffing, and MDS solutions. The company was incorporated in 2006 and is based in Grand Cayman, Grand Cayman.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 165
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 6550

Financial Performance

In 2024, Polaris Group's revenue was 107.00 million, an increase of 1330.29% compared to the previous year's 7.48 million. Losses were -2.50 billion, 67.7% more than in 2023.